Paolo Chetta

Paolo Chetta

Auto-generated profile, based on publicly available information

Paolo Chetta

University of Milan, Milan, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2024 in Cancer Research
Verified
Journal Article
Open access
NBNadia Boufaied
Nadia Boufaied
PCPaolo Chetta
Paolo Chetta
THTarek Hallal
Tarek Hallal
Stefano CacciatoreStefano Cacciatore
Stefano Cacciatore
DLDaniela Lalli
Daniela Lalli
GZGiorgia Zadra
Giorgia Zadra
Cancer cells exhibit metabolic plasticity to meet oncogene-driven dependencies while coping with nutrient availability. A better understanding of how systemic metabolism impacts the accumulation of metabolites that reprogram the tumor microenvironment (TME) and drive cancer could facilitate development of precision nutrition approaches. Using the Hi-MYC prostate cancer mouse model, we demonstrated that an obesogenic high-fat diet (HFD) rich in saturated fats accelerates the development of c-MYC–driven invasive prostate cancer through metabolic rewiring. Although c-MYC modulated key metabolic pathways, interaction with an obesogenic HFD was necessary to induce glycolysis and lactate accumulation in tumors. These metabolic changes were associated with augmented infiltration of CD206+ and PD-L1+ tumor-associated macrophages (TAM) and FOXP3+ regulatory T cells, as well as with the activation of transcriptional programs linked to disease progression and therapy resistance. Lactate itself also stimulated neoangiogenesis and prostate cancer cell migration, which were significantly reduced following treatment with the lactate dehydrogenase inhibitor FX11. In patients with prostate cancer, high saturated fat intake and increased body mass index were associated with tumor glycolytic features that promote the infiltration of M2-like TAMs. Finally, upregulation of lactate dehydrogenase, indicative of a lactagenic phenotype, was associated with a shorter time to biochemical recurrence in independent clinical cohorts. This work identifies cooperation between genetic drivers and systemic metabolism to hijack the TME and promote prostate cancer progression through oncometabolite accumulation. This sets the stage for the assessment of lactate as a prognostic biomarker and supports strategies of dietary intervention and direct lactagenesis blockade in treating advanced prostate cancer. Significance: Lactate accumulation driven by high-fat diet and MYC reprograms the tumor microenvironment and promotes prostate cancer progression, supporting the potential of lactate as a biomarker and therapeutic target in prostate cancer. See related commentary by Frigo, p. 1742

15 August 2020 in Cancer Research
Verified
Journal Article
Closed access
GGGabriela Gremel
Gabriela Gremel
MIMaria A. Impagnatiello
Maria A. Impagnatiello
SCSebastian Carotta
Sebastian Carotta
OSOtmar Schaaf
Otmar Schaaf
PCPaolo M. Chetta
Paolo M. Chetta
NKNorbert Kraut
Norbert Kraut
Introduction: Stimulator of interferon genes (STING) is activated by cyclic dinucleotides that are generated by cyclic GMP-AMP synthase in the presence of cytosolic DNA, resulting in a type 1 interferon response and the secretion of pro-inflammatory cytokines. BI-STING mimics the natural ligand of STING and hijacks the STING signaling pathway to trigger a potent anti-tumor immune response. Here we report the pre-clinical characterization of BI-STING in human cells lines in vitro, in human ex vivo systems and in vivo mouse models. Methods: Activity and specificity of BI-STING were tested in vitro in the human monocytic leukemia cell line THP1. Target engagement was confirmed using ex vivo studies in human whole blood and in human precision cut colorectal cancer slices. For in vivo studies, BI-STING was administered intratumorally (i.tu.) in a range of subcutaneous, syngeneic murine tumor models. The modulation of cytokine secretion over time was recorded and the induction of a tumor-specific immune response demonstrated. Results: Using THP1 cells, activation of down-stream signaling events by BI-STING was seen specifically in STING wild type, but not STING knock out cells. Ex vivo treatment of human whole blood and human precision cut colorectal cancer slices with BI-STING resulted in the significant induction of cytokine secretion (including IFNβ) and in an array of transcriptional changes associated with the activation of STING signaling. Treatment of tumor-bearing mice with a single dose of BI-STING i.tu. led to a transient increase of cytokine levels in tumor and plasma. In all tested models, i.tu. administration of BI-STING resulted in dose-dependent local tumor control. Importantly, animals whose primary tumor was cured by BI-STING treatment did not develop tumors when re-challenged with the same tumor cell line and an abscopal delay in tumor growth was seen for non-injected (or anenestic) lesions in mice carrying bilateral tumors. Abscopal tumor control was further improved when combined with anti-PD-1. Finally, ELISpot analysis resulted in a significantly increased number of immunospots in splenocytes from BI-STING treated animals as compared to vehicle control mice, confirming the induction of a tumor-specific immune response. Conclusions: BI-STING is a potent and specific inducer of the STING signaling pathway. In addition to local tumor control, i.tu. treatment with BI-STING results in a systemic anti-tumor immune response in mice, which was enhanced upon anti-PD-1 combination. A clinical trial to evaluate i.tu. administration of BI-STING alone and in combination with anti-PD-1 in patients with advanced solid tumors is ongoing. Citation Format: Gabriela Gremel, Maria A. Impagnatiello, Sebastian Carotta, Otmar Schaaf, Paolo M. Chetta, Thorsten Oost, Thomas Zichner, Marco Hofmann, Sophia Blake, Tom Bretschneider, Martin Fleck, Achim Grube, Herbert Nar, Georg Rast, Esther Schmidt, Ute Klinkhardt, Kirsten Arndt-Schmitz, Thorsten Laux, Vittoria Zinzalla, Jonathon Sedgwick, Norbert Kraut. Potent induction of a tumor-specific immune response by a cyclic dinucleotide STING agonist [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4522.

22 July 2024
Verified
Other
Open access
PDF file
NBNadia Boufaied
Nadia Boufaied
PCPaolo Chetta
Paolo Chetta
THTarek Hallal
Tarek Hallal
Stefano CacciatoreStefano Cacciatore
Stefano Cacciatore
DLDaniela Lalli
Daniela Lalli
GZGiorgia Zadra
Giorgia Zadra
Supplementary Figure S10 shows the output of human-based deconvolution model QuanTIseq.

22 July 2024
Verified
Other
Open access
PDF file
NBNadia Boufaied
Nadia Boufaied
PCPaolo Chetta
Paolo Chetta
THTarek Hallal
Tarek Hallal
Stefano CacciatoreStefano Cacciatore
Stefano Cacciatore
DLDaniela Lalli
Daniela Lalli
GZGiorgia Zadra
Giorgia Zadra
Supplementary Figure S1 shows the systemic effects of HFD.

22 July 2024
Verified
Other
Open access
PDF file
NBNadia Boufaied
Nadia Boufaied
PCPaolo Chetta
Paolo Chetta
THTarek Hallal
Tarek Hallal
Stefano CacciatoreStefano Cacciatore
Stefano Cacciatore
DLDaniela Lalli
Daniela Lalli
GZGiorgia Zadra
Giorgia Zadra
Supplementary Figure S9 shows GSEA_Hallmark results in human PCa

22 July 2024
Verified
Other
Open access
PDF file
NBNadia Boufaied
Nadia Boufaied
PCPaolo Chetta
Paolo Chetta
THTarek Hallal
Tarek Hallal
Stefano CacciatoreStefano Cacciatore
Stefano Cacciatore
DLDaniela Lalli
Daniela Lalli
GZGiorgia Zadra
Giorgia Zadra
Supplementary Figure S6 includes scRNA-seq data showing that Luminal (high Ly6d) cells in MYC-transformed DLP display glycolytic features.